Musselwhite Laura W, Andrade Bruno B, Ellenberg Susan S, Tierney Ann, Belaunzaran-Zamudio Pablo F, Rupert Adam, Lederman Michael M, Sanne Ian, Sierra Madero Juan G, Sereti Irini
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), 10 Center Drive, Bethesda, MD 20892, USA; Duke Hubert Yeargan Center for Global Health, Duke University, 310 Trent Drive, Duke Box 90518, Durham, NC 27708, USA.
Laboratory of Parasitic Diseases, NIAID, NIH, 50 South Drive, Bethesda, MD 20892, USA; Unidade de Medicina Investigativa, Laboratório Integrado de Microbiologia e Imunorregulação (LIMI), Centro de Pesquisas Gonçalo Moniz (CPqGM), Fundação Oswaldo Cruz (FIOCRUZ), Salvador 40296-710, Brazil; Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER Initiative), Brazilian Institute for Tuberculosis Research, José Silveira Foundation, Salvador, Brazil.
EBioMedicine. 2016 Jan 14;4:115-23. doi: 10.1016/j.ebiom.2016.01.016. eCollection 2016 Feb.
To determine the immunological profile most important for IRIS prediction, we evaluated 20 baseline plasma biomarkers in Acquired Immunodeficiency Syndrome (AIDS) patients initiating antiretroviral therapy (ART). Patients were enrolled in a randomized, placebo-controlled ART initiation trial in South Africa and Mexico to test whether maraviroc could prevent IRIS. Participants were classified prospectively as having IRIS within 6 months of ART initiation. Twenty plasma biomarkers were measured at study enrollment for 267 participants. Biomarkers were tested for predicting IRIS with adjustment for covariates chosen through forward stepwise selection. Sixty-two participants developed IRIS and of these 19 were tuberculosis (TB)-IRIS. Baseline levels of vitamin D and higher d-dimer, interferon gamma (IFNγ), and sCD14 were independently associated with risk of IRIS in multivariate analyses. TB-IRIS cases exhibited a distinct biosignature from IRIS related to other pathogens, with increased levels of C-reactive protein (CRP), sCD14, IFNγ, and lower levels of Hb that could be captured by a composite risk score. Elevated markers of Type 1 T helper (Th1) response, monocyte activation, coagulation and low vitamin D were independently associated with IRIS risk. Interventions that decrease immune activation and increase vitamin D levels warrant further study.
为确定对免疫重建炎症综合征(IRIS)预测最为重要的免疫特征,我们评估了开始抗逆转录病毒治疗(ART)的获得性免疫缺陷综合征(AIDS)患者的20种基线血浆生物标志物。患者参与了在南非和墨西哥开展的一项随机、安慰剂对照的ART启动试验,以测试马拉维若是否可预防IRIS。前瞻性地将参与者分类为在ART启动后6个月内发生IRIS。对267名参与者在研究入组时测量了20种血浆生物标志物。对生物标志物进行测试以预测IRIS,并对通过向前逐步选择法选择的协变量进行调整。62名参与者发生了IRIS,其中19例为结核病(TB)-IRIS。在多变量分析中,维生素D的基线水平以及较高的D-二聚体、干扰素γ(IFNγ)和可溶性CD14与IRIS风险独立相关。TB-IRIS病例表现出与其他病原体相关的IRIS不同的生物特征,C反应蛋白(CRP)、可溶性CD14、IFNγ水平升高,血红蛋白(Hb)水平降低,这些可通过综合风险评分来体现。1型辅助性T细胞(Th1)反应、单核细胞活化、凝血的升高标志物以及低维生素D水平与IRIS风险独立相关。降低免疫激活并提高维生素D水平的干预措施值得进一步研究。